Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay

Giovannino Silvestri, PhD, Justin Ellis, Lorenzo Stramucci, PhD, Jason G Harb, PhD, Paolo Neviani, PhD, Guido Marcucci, MD, Denis-Claude Roy, MD, Peter Hokland, MD DMSc, Dragana Milojkovic, Alistair Reid, Jane F. Apperley, Ferenc M Livak, PhD, Maria R. Baer, MD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD

Blood (2014) 124 (21): 4529.

https://doi.org/10.1182/blood.V124.21.4529.4529

Published: 2014

Journal Articles

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias

Blood (2013) 122 (17): 3034–3044.

https://doi.org/10.1182/blood-2013-04-495374

Published: 2013

Includes: Supplemental data

Journal Articles

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Blood (2013) 122 (11): 1923–1934.

https://doi.org/10.1182/blood-2013-03-492181

Published: 2013

Includes: Supplemental data

Journal Articles

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, Ph.D, Jason G Harb, Ph.D, Gregory Ferenchak, Justin Ellis, Guido Marcucci, MD, Yosef Landesman, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, Danilo Perrotti, MD, Ph.D

Blood (2012) 120 (21): 35.

https://doi.org/10.1182/blood.V120.21.35.35

Published: 2012

Journal Articles

Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia

Vera Magistroni, PhD, Nitesh Sharma, Rocco Piazza, MD, PhD, Jason G Harb, Ph.D, Roberta Spinelli, M.Sc., Alessandra Pirola, M.Sc., Justin Ellis, Kim Dong-Wook, Danilo Perrotti, MD, Ph.D, Carlo Gambacorti-Passerini, MD

Blood (2012) 120 (21): 3727.

https://doi.org/10.1182/blood.V120.21.3727.3727

Published: 2012

Journal Articles

Combined Pharmacologic Inhibition of Bcl-Xl/Bcl-2 and mTORC1/2 Survival Signals Trigger Apoptosis in BCR-ABL1 + in Vitro Models of Blast Crisis Chronic Myelogenous Leukemia (CML-BC), and Primary CD34 + /CD38 − Stem and CD34 + progenitor Cells From CML-BC Patients

Jason G Harb, Ph.D, Paolo Neviani, PhD, Claudia S Huettner, PhD, Guido Marcucci, MD, Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 2738.

https://doi.org/10.1182/blood.V118.21.2738.2738

Published: 2011

Journal Articles

FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34 + Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, PhD, S. A Saddoughi, Paolo Neviani, PhD, Jason G Harb, Ph.D, Besim Ogretmen, PhD, Robert Bittman, Ph.D, Ross L Levine, MD, Alfonso Quintás-Cardama, MD, Guido Marcucci, MD, Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 2494.

https://doi.org/10.1182/blood.V118.21.2494.2494

Published: 2011

Journal Articles

Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity,

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, PhD, Jason G Harb, Ph.D, Carolyn Paisie, B.S., Guido Marcucci, MD, Sharon Shacham, PhD, Michael Kauffman, MD, Ph.D., Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 3758.

https://doi.org/10.1182/blood.V118.21.3758.3758

Published: 2011

Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Blood (2010) 116 (21): 515.

https://doi.org/10.1182/blood.V116.21.515.515

Published: 2010

Journal Articles

The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML.

Jason G Harb, Paolo Neviani, Joshua J Oaks, Guido Marcucci, MD, Peter Hokland, MD, DMSC, Denis-Claude Roy, MD, FRCPC, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 1222.

https://doi.org/10.1182/blood.V116.21.1222.1222

Published: 2010

Journal Articles

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, S. A Saddoughi, Christopher Walker, Paolo Neviani, Jason G Harb, Y. Ma, Srdan Verstovsek, MD, PhD, Guido Marcucci, MD, Roger Briesewitz, Robert Bittman, Ching-Shih Chen, Alfonso Quintas-Cardama, MD, Besim Ogretmen, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 775.

https://doi.org/10.1182/blood.V116.21.775.775

Published: 2010

Journal Articles

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Christopher Walker, B.S., Joshua J Oaks, B.S., Paolo Neviani, Ph.D, Jason G Harb, Ph.D., Ramasamy Santhanam, Ph.D, Y. Ma, Guido Marcucci, MD, James Van Brocklyn, Ph.D, Ching-Shih Chen, Ph.D, Robert Bittman, Ph.D, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 2901.

https://doi.org/10.1182/blood.V116.21.2901.2901

Published: 2010

Journal Articles

Loss of Bcl-x in Ph + B-ALL increases cellular proliferation and does not inhibit leukemogenesis

Jason G. Harb, Brenda I. Chyla, Claudia S. Huettner

Blood (2008) 111 (7): 3760–3769.

https://doi.org/10.1182/blood-2007-08-108803

Published: 2008

Journal Articles

A Novel Role for Bcl-x L in the Context of p210 BCR/ABL B Cell Acute Lymphoblastic Leukemia (B-ALL).

Jason G. Harb, PhD, Brenda I. Chyla, PhD, Claudia S. Huettner, PhD

Blood (2007) 110 (11): 156.

https://doi.org/10.1182/blood.V110.11.156.156

Published: 2007

Journal Articles

Loss of Bcl-x Does Not Ameliorate Chronic Myeloid Leukemia in an Inducible Murine Model System.

Brenda J. Chyla, PhD, Jason G. Harb, Ph.D., Claudia S. Huettner, Ph.D.

Blood (2007) 110 (11): 1000.

https://doi.org/10.1182/blood.V110.11.1000.1000

Published: 2007

Journal Articles

Genetic Deletion of Bcl-x Reveals a Potential Role in Governing Stem Cell Homeostasis.

Brenda J. Chyla, PhD, Jason G. Harb, Ph.D., Claudia S. Huettner, Ph.D.

Blood (2006) 108 (11): 1349.

https://doi.org/10.1182/blood.V108.11.1349.1349

Published: 2006

Journal Articles

Bcl-x Is Indispensable for the Development of Natural Killer Cells.

Jason G. Harb, PhD, Malarkannan Subramaniam, PhD, Claudia S. Huettner, PhD

Blood (2005) 106 (11): 340.

https://doi.org/10.1182/blood.V106.11.340.340

Published: 2005

NARROW

MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia

Combined Pharmacologic Inhibition of Bcl-Xl/Bcl-2 and mTORC1/2 Survival Signals Trigger Apoptosis in BCR-ABL1 + in Vitro Models of Blast Crisis Chronic Myelogenous Leukemia (CML-BC), and Primary CD34 + /CD38 − Stem and CD34 + progenitor Cells From CML-BC Patients

FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34 + Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML.

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Loss of Bcl-x in Ph + B-ALL increases cellular proliferation and does not inhibit leukemogenesis

A Novel Role for Bcl-x L in the Context of p210 BCR/ABL B Cell Acute Lymphoblastic Leukemia (B-ALL).

Loss of Bcl-x Does Not Ameliorate Chronic Myeloid Leukemia in an Inducible Murine Model System.

Genetic Deletion of Bcl-x Reveals a Potential Role in Governing Stem Cell Homeostasis.

Bcl-x Is Indispensable for the Development of Natural Killer Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only